Common marmoset (Callithrix jacchus) as a primate model of dengue virus infection: Development of high levels of viraemia and demonstration of protective immunity

Journal of General Virology

Volumn 92, Issue 10, 2011, Pages 2272-2280

  Omatsu, Tsutomu ^a   Moi, Meng Ling ^a   Hirayama, Takanori ^a   Takasaki, Tomohiko ^a   Nakamura, Shinichiro ^b   Tajima, Shigeru ^a   Ito, Mikako ^a   Yoshida, Tomoyuki ^c   Saito, Akatsuki ^c   Katakai, Yuko ^c   Akari, Hirofumi ^c,d   Kurane, Ichiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NONSTRUCTURAL PROTEIN 1; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALLITRICHINAE; DENGUE; DENGUE VIRUS 2; IMMUNOHISTOCHEMISTRY; LIVER; LYMPH NODE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; THYMUS; VIREMIA;

ANIMAL STRUCTURES; ANIMALS; ANTIBODIES, VIRAL; CALLITHRIX; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOHISTOCHEMISTRY; MALE; VIRAL LOAD; VIREMIA;

ANIMALIA; CALLITHRIX JACCHUS; DENGUE VIRUS; PRIMATES;

EID: 80052922848     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.031229-0     Document Type: Article

References (32)

1. Alcon, S., Talarmin, A., Debruyne, M., Falconar, A., Deubel, V. & Flamand, M. (2002). Enzyme-linked immunosorbent assay specific to Dengue virus type 1 nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 40, 376-381.
2. Balsitis, S. J., Williams, K. L., Lachica, R., Flores, D., Kyle, J. L., Mehlhop, E., Johnson, S., Diamond, M. S., Beatty, P. R. & Harris, E. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6, e1000790.
3. Bente, D. A. & Rico-Hesse, R. (2006). Models of dengue virus infection. Drug Discov Today Dis Models 3, 97-103.
4. Bente, D. A., Melkus, M. W., Garcia, J. V. & Rico-Hesse, R. (2005). Dengue fever in humanized NOD/SCID mice. J Virol 79, 13797-13799.
5. Bernardo, L., Izquierdo, A., Prado, I., Rosario, D., Alvarez, M., Santana, E., Castro, J., Martínez, R., Rodríguez, R. & other authors (2008). Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol 15, 439-446.
6. Bhamarapravati, N., Tuchinda, P. & Boonyapaknavik, V. (1967). Pathology of Thailand haemorrhagic fever: a study of 100 autopsy cases. Ann Trop Med Parasitol 61, 500-510.
7. Blair, P. J., Kochel, T. J., Raviprakash, K., Guevara, C., Salazar, M., Wu, S. J., Olson, J. G. & Porter, K. R. (2006). Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys. Vaccine 24, 1427-1432.
8. de Araújo, J. M., Schatzmayr, H. G., de Filippis, A. M., Dos Santos, F. B., Cardoso, M. A., Britto, C., Coelho, J. M. & Nogueira, R. M. (2009). A retrospective survey of dengue virus infection in fatal cases from an epidemic in Brazil. J Virol Methods 155, 34-38.
9. Flamand, M., Megret, F., Mathieu, M., Lepault, J., Rey, F. A. & Deubel, V. (1999). Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylationdependent fashion. J Virol 73, 6104-6110.
10. Goncalvez, A. P., Engle, R. E., St Claire, M., Purcell, R. H. & Lai, C.-J. (2007). Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104, 9422-9427.
11. Guirakhoo, F., Pugachev, K., Zhang, Z., Myers, G., Levenbook, I., Draper, K., Lang, J., Ocran, S., Mitchell, F. & other authors (2004). Safety and efficacy of chimeric Yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78, 4761-4775.
12. Halstead, S. B. (2007). Dengue. Lancet 370, 1644-1652.
13. Ito, M., Takasaki, T., Yamada, K., Nerome, R., Tajima, S. & Kurane, I. (2004). Development and evaluation of fluorogenic TaqMan reverse transcriptase PCR assays for detection of dengue virus types 1 to 4. J Clin Microbiol 42, 5935-5937.
14. Ito, M., Mukai, R. Z., Takasaki, T., Kotaki, A. & Kurane, I. (2010). Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus. Arch Virol 155, 1617-1624.
15. Jessie, K., Fong, M. Y., Devi, S., Lam, S. K. & Wong, K. T. (2004). Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J Infect Dis 189, 1411-1418.
16. Koraka, P., Benton, S., van Amerongen, G., Stittelaar, K. J. & Osterhaus, A. D. (2007). Efficacy of a live attenuated tetravalent candidate dengue vaccine in nai{dotless}̈ve and previously infected cynomolgus macaques. Vaccine 25, 5409-5416.
17. Libraty, D. H., Endy, T. P., Houng, H. S., Green, S., Kalayanarooj, S., Suntayakorn, S., Chansiriwongs, W., Vaughn, D. W., Nisalak, A. & other authors (2002a). Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185, 1213-1221.
18. Libraty, D. H., Young, P. R., Pickering, D., Endy, T. P., Kalayanarooj, S., Green, S., Vaughn, D. W., Nisalak, A., Ennis, F. A. & Rothman, A. L. (2002b). High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 186, 1165-1168.
19. Mackenzie, J. M., Jones, M. K. & Young, P. R. (1996). Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication. Virology 220, 232-240.
20. Marchette, N. J., Halstead, S. B., Jr, Falkler, W. A., Jr, Stenhouse, A. & Nash, D. (1973). Studies on the pathogenesis of dengue infection in monkeys. 3. Sequential distribution of virus in primary and heterologous infections. J Infect Dis 128, 23-30.
21. Mizuno, Y., Kotaki, A., Harada, F., Tajima, S., Kurane, I. & Takasaki, T. (2007). Confirmation of dengue virus infection by detection of dengue virus type 1 genome in urine and saliva but not in plasma. Trans R Soc Trop Med Hyg 101, 738-739.
22. Moi, M. L., Takasaki, T., Kotaki, A., Tajima, S., Lim, C. K., Sakamoto, M., Iwagoe, H., Kobayashi, K. & Kurane, I. (2010a). Importation of dengue virus type 3 to Japan from Tanzania and Cote d'Ivoire. Emerg Infect Dis 16, 1770-1772.
23. Moi, M. L., Lim, C. K., Kotaki, A., Takasaki, T. & Kurane, I. (2010b). Discrepancy in dengue virus neutralizing antibody titers between plaque reduction neutralizing tests with Fcc receptor (FccR)-negative and FccR-expressing BHK-21 cells. Clin Vaccine Immunol 17, 402-407.
24. Onlamoon, N., Noisakran, S., Hsiao, H. M., Duncan, A., Villinger, F., Ansari, A. A. & Perng, G. C. (2010). Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 115, 1823-1834.
25. Poloni, T. R., Oliveira, A. S., Alfonso, H. L., Galvão, L. R., Amarilla, A. A., Poloni, D. F., Figueiredo, L. T. & Aquino, V. H. (2010). Detection of dengue virus in saliva and urine by real time RT-PCR. Virol J 7, 22.
26. Raviprakash, K., Wang, D., Ewing, D., Holman, D. H., Block, K., Woraratanadharm, J., Chen, L., Hayes, C., Dong, J. Y. & Porter, K. (2008). A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 82, 6927-6934.
27. Rosen, L., Drouet, M. T. & Deubel, V. (1999). Detection of dengue virus RNA by reverse transcription-polymerase chain reaction in the liver and lymphoid organs but not in the brain in fatal human infection. Am J Trop Med Hyg 61, 720-724.
28. Schiavetta, A. M., Harre, J. G., Wagner, E., Simmons, M. & Raviprakash, K. (2003). Variable susceptibility of the owl monkey (Aotus nancymae) to four serotypes of dengue virus. Contemp Top Lab Anim Sci 42, 12-20.
29. Shrestha, B., Brien, J. D., Sukupolvi-Petty, S., Austin, S. K., Edeling, M. A., Kim, T., O'Brien, K. M., Nelson, C. A., Johnson, S. & other authors (2010). The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6, e1000823.
30. Vaughn, D.W., Green, S., Kalayanarooj, S., Innis, B. L., Nimmannitya, S., Suntayakorn, S., Rothman, A. L., Ennis, F. A. & Nisalak, A. (1997). Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 176, 322-330.
31. Whitehead, S. S., Hanley, K. A., Jr, Blaney, J. E., Jr, Gilmore, L. E., Elkins, W. R. & Murphy, B. R. (2003). Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21, 4307-4316.
32. WHO (2002). Dengue and dengue haemorrhagic fever. Fact sheet no. 117.